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A Nail in the Coffin
of Troponin Measurements
After Percutaneous
Coronary Intervention*
Cindy L. Grines, MD, Simon Dixon, MBCHB
oyal Oak, Michigan
Over the past several decades, we have made substantial
progress in the early diagnosis and management of acute
myocardial infarction (AMI). Throughout most of our
careers, the diagnosis of AMI required that at least 2 of 3
criteria were met: prolonged ischemic symptoms, diagnostic
electrocardiographic (ECG) changes, and elevation of total
creatine kinase (CK) with creatine kinase-myocardial band
(CK-MB) exceeding 3 times the upper limit of normal.
Over the past several decades, these diagnostic criteria were
repeatedly validated with evidence showing that the level of
CK-MB was highly predictive of infarct size, development
of heart failure, as well as short- and long-term mortality.
Given these findings, why have many hospitals abandoned
measurement of CK-MB in favor of troponin?
See page 653
Unfortunately CK is present in other tissues, such as
skeletal muscle or brain; thus the clinician used the % MB
index and the typical rise and fall to determine the clinical
significance of any CK elevation. It was particularly prob-
lematic to decipher enzyme elevations in patients with
significant trauma or after surgery when skeletal muscle
injury occurred. At the same time, coronary reperfusion
therapy was becoming mainstream, and a more rapid means
of diagnosing AMI was thought to be extremely important
(although even in 2011, reperfusion is administered on the
basis of ECG findings and not enzyme elevations).
Cardiac specific troponin isoforms (both T and I) are
present only in cardiac myocytes and not in skeletal muscle;
thus measurement of this biomarker was thought to be a
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confirmed “greater specificity” of troponin compared with
CK (1). Recombinant human cardiac specific troponin-T
assays have further improved specificity by eliminating cross
reactivity with skeletal muscle troponin. Accordingly, a
consensus opinion from the European Society of Cardiology
and American College of Cardiology “redefined” myocardial
infarction (MI) and promoted the use of cardiac troponin as
the preferred marker, given its “nearly absolute myocardial
tissue specificity, high sensitivity, and ability of the marker
to reflect microscopic zones of myocardial necrosis” (2). It is
clear that troponin allows an earlier diagnosis in patients
who present with chest pain and have nondiagnostic ECGs.
Furthermore, troponin elevations are of prognostic impor-
tance in studies of acute coronary syndrome (ACS) patients
(3) and allow the physician to target high-risk ACS patients
with more aggressive therapies.
However, the diagnostic and prognostic value of troponin
falls off in patient populations other than the ACS group.
Although elevations are thought to be diagnostic of cardiomy-
ocyte “injury,” troponin measurements are so sensitive that
elevations are observed in numerous non-AMI settings, in-
cluding renal insufficiency, post-partum hemorrhage, conges-
tive heart failure, cardiac amyloidosis, heart transplant, pericar-
ditis, valvular heart disease, cardioversion, septic shock,
pulmonary embolism, and vigorous exercise (4) as well as
because of laboratory error or analytical interferences (5). Due
to complaints of false positive troponin measurements, the
U.S. Food and Drug Administration issued a Medical Device
Safety Report, noting that “few commercially available assays
can achieve the level of imprecision recommended by practice
guidelines” (6). Thus, although troponin measurements enable
improved sensitivity, the clinician might be faced with dimin-
ished specificity for diagnosing MI.
This is particularly problematic when dealing with post–
percutaneous coronary intervention (PCI) enzyme elevations.
Some early studies using less sensitive troponin assays and
higher threshold values found elevated levels after PCI to be of
prognostic importance (7). Other authors reported value only if
pre-procedural troponin was normal and post-PCI values
exceeded 5 times the upper limit of normal (8,9). However,
whether troponin measurements add additional prognostic
value beyond the measurement of CK-MB remains uncertain
(10–12). Moreover, a large prospective trial reported that
periprocedural MI was a marker of baseline risk and athero-
sclerotic burden but did not have prognostic significance (13).
The recent introduction of more sensitive troponin assays
has further complicated the interpretation value of post-
procedure enzyme elevations (14–16). Depending on the
patient population, manufacturer assay, and defined thresh-
old level for myocardial necrosis, approximately 30% to 50%
of patients might have an elevated troponin level after
elective PCI. In many cases, a post-PCI troponin increase
might occur in an otherwise straightforward procedure in a
patient who is asymptomatic.
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99th percentile for upper limit of troponin I is 0.05 ng/ml.
Therefore with the currently recommended threshold of 3
99th percentile, a troponin leak of 0.15 ng/ml would constitute
a type 4a periprocedural MI. This extremely low threshold for
diagnosis of PCI-related MI has far-reaching implications for
patient care, outcome reporting, and clinical trial design. Not
surprisingly, very few physicians or centers routinely measure
post-procedure troponin levels (17). Therefore, given the high
frequency of troponin leak after coronary intervention, the key
question should be: “When is a post-PCI troponin elevation
clinically meaningful?”
In this issue of the Journal, Lim et al. (18) provide
mportant new insights regarding post-procedural troponin
easurement. With a highly sensitive assay, 26 of 32 (82%)
atients undergoing multivessel intervention were found to
ave a troponin elevation 3 the upper limit of normal,
thereby meeting criteria for MI. However, only 5 of these
26 patients had evidence of myocardial necrosis assessed by
late gadolinium enhancement on cardiac magnetic reso-
nance imaging. Abnormal levels of CK-MB better pre-
dicted magnetic resonance imaging–defined infarction.
Moreover, changes in inflammatory markers (a marker of
myocardial injury) were closely correlated to levels of
CK-MB but not troponin. The authors concluded that
current troponin thresholds are overly sensitive and fail to
accurately discriminate patients with MI. In further analy-
sis, a troponin level of 2.7 ng/ml was considered an
“optimal” threshold for defining procedural MI.
Although a threshold troponin value of 2.7 or 3.0 ng/ml
for defining MI seems reasonable, this will require valida-
tion in a larger cohort of patients with long-term outcome
data. Moreover, because the size of delayed hyperenhance-
ment shrinks with time, further imaging studies are needed
to determine what extent of injury on early post-PCI studies
impacts late ventricular function or clinical outcomes.
Should these data lead us to abandon measuring cardiac
biomarkers after PCI? We think not. In fact, we believe that
measurement of a marker is helpful for quality assurance and
outcomes research, but at this point in time, we discourage
use of high-sensitivity troponin assays for determination of
PCI-related MI. Rather, we recommend continued use of
CK-MB measurements after PCI, on the basis of well-
accepted standards and a very large body of clinical trial
data. Some might argue this is simply an interventionalist
“head-in-the-sand” approach, but until such time that
minor troponin leaks detected with high-sensitivity assays
are shown to mechanistically impact patient outcome, their
routine measurement for having PCI is of limited value.
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